Key result
A cumulative doxorubicin dose of 12 mg/kg significantly reduced left ventricular ejection fraction compared to control (58.4% vs 68.3%) and induced myocardial fibrosis with an acceptable 30% mortality rate.
Why the study?
Doxorubicin is used to induce dilated cardiomyopathy in experimental models, but the most effective protocol required definition.
What is the most effective cumulative dose of doxorubicin to induce a dilated cardiomyopathy model in male Wistar rats?
What is the most effective cumulative dose of doxorubicin to induce a dilated cardiomyopathy model in male Wistar rats?
Absolute Event Rate: 58.4% vs 68.3%
p-value: p=<0.01
This study aims to define the optimal cumulative dose of doxorubicin to induce a dilated cardiomyopathy model in rats.
May guide preclinical rat model optimization; leaves open translation to human cardiomyopathy research.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2022) studied Dilated Cardiomyopathy (n=86). Doxorubicin vs. Saline solution was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.01). A cumulative doxorubicin dose of 12 mg/kg significantly reduced left ventricular ejection fraction compared to control (58.4% vs 68.3%) and induced myocardial fibrosis with an acceptable 30% mortality rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: